Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Related Citations for PubMed (Select 23714551)

1.

Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.

Bartlett NL.

Am Soc Clin Oncol Educ Book. 2013:374-80. doi: 10.1200/EdBook_AM.2013.33.374.

2.

Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.

Pavlovsky S, Corrado C, Pavlovsky MA, Prates MV, Zoppegno L, Giunta M, Cerutti I, Palomino E, Pagani F, Lastiri F, Bar D, Bezares RF, Avila G.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):181-5. doi: 10.3816/CLML.2010.n.028.

PMID:
20511162
3.

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group.

N Engl J Med. 2012 Feb 2;366(5):399-408. doi: 10.1056/NEJMoa1111961. Epub 2011 Dec 11.

4.

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.

J Clin Oncol. 2010 Sep 20;28(27):4199-206. doi: 10.1200/JCO.2010.29.8018. Epub 2010 Aug 16.

5.

Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.

Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.

J Clin Oncol. 2012 Nov 20;30(33):4117-23. doi: 10.1200/JCO.2012.41.8137. Epub 2012 Oct 8. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590.

6.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM; Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).

Ann Oncol. 2013 Dec;24(12):3065-9. doi: 10.1093/annonc/mdt389. Epub 2013 Oct 11.

7.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.

N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067.

8.

A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?

Hamed RH, Anter AH, Awad IA.

Hematol Oncol Stem Cell Ther. 2012;5(1):36-41. doi: 10.5144/1658-3876.2012.36.

9.

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.

Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.

PMID:
24239220
10.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V.

J Clin Oncol. 2007 Aug 10;25(23):3495-502. Epub 2007 Jul 2.

11.

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi.

J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19.

12.

Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.

Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):860-5. Epub 2005 May 31.

PMID:
15925455
13.

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J Jr, Buccheri V, Meneghetti JC.

J Nucl Med. 2010 Sep;51(9):1337-43. doi: 10.2967/jnumed.109.073197. Epub 2010 Aug 18. Erratum in: J Nucl Med. 2010 Oct;51(10):1658.

14.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C.

J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17.

PMID:
24637998
15.

ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.

Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A; Intergruppo Italiano Linfomi (IIL).

Ann Oncol. 2008 Apr;19(4):763-8. doi: 10.1093/annonc/mdm575. Epub 2008 Jan 6.

16.

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.

Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P.

J Clin Oncol. 2004 Jul 15;22(14):2835-41. Epub 2004 Jun 15.

17.

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK.

Ann Oncol. 2009 Nov;20(11):1848-53. doi: 10.1093/annonc/mdp071. Epub 2009 Jun 18.

19.

Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.

Karmiris TD, Grigoriou E, Tsantekidou M, Spanou E, Mihalakeas H, Baltadakis J, Apostolidis J, Pagoni M, Karakasis D, Bakiri M, Mitsouli C, Harhalakis N, Nikiforakis E.

Leuk Lymphoma. 2003 Sep;44(9):1523-8.

PMID:
14565654
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk